Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramantamig - Janssen Research & Development

Next Previous
Drug Profile

Ramantamig - Janssen Research & Development

Alternative Names: JNJ-5322; JNJ-79635322

Latest Information Update: 15 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma

Most Recent Events

  • 31 May 2026 Phase-III clinical trials in Multiple myeloma (Second-line therapy or greater) in Taiwan, Turkey, USA, Israel (SC) (NCT07518186)
  • 13 Apr 2026 Janssen Research & Development plans the phase III TRIlogy-5 trial for Multiple Myeloma (Second-line therapy or greater) in June 2026 (SC, Injection) (NCT07518186)
  • 08 Feb 2026 Janssen Research & Development initiates enrollment in the phase II TRIlogy-3 trial in Multiple myeloma (Second-line therapy or greater) in USA, Japan (SC, Injection) (NCT07266441)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top